Pneumocystis Pneumonia

Pneumocystis pneumonia (PCP) is a life-threatening opportunistic fungal infection caused by Pneumocystis jirovecii, occurring almost exclusively in immunocompromised hosts. It remains the most common AIDS-defining illness and carries a mortality of 10–20% in HIV-positive and 30–50% in HIV-negative immunocompromised patients. [1-3]

1. History

• Onset pattern is key: In HIV-positive patients, symptoms develop subacutely over days to weeks (progressive dyspnea, dry cough, low-grade fever, chest discomfort). In HIV-negative immunocompromised patients, onset is more acute and fulminant, often over days. [1-2][4]
• Characterize dyspnea: initially exertional, progressing to rest dyspnea; ask about exercise tolerance trajectory
• Cough is typically nonproductive; productive cough suggests bacterial co-infection [1-2]
• Ask about fever pattern, night sweats, weight loss, oral thrush (marker of immunosuppression)
• Determine immunosuppressive context: HIV status, CD4 count, transplant history, chemotherapy, corticosteroid use (dose and duration), biologic agents
• Critical question: Is the patient on PCP prophylaxis? ~95% of PCP cases occur in patients not receiving prophylaxis [5]
• Important negatives: pleuritic chest pain (consider pneumothorax), hemoptysis, rigors (more suggestive of bacterial etiology)

2. Alarm Features

• Severe hypoxemia: PaO₂ <70 mmHg or A-a gradient ≥35 mmHg on room air — defines moderate-to-severe disease and triggers adjunctive corticosteroids [1]
• Respiratory failure requiring mechanical ventilation — mortality rises to 50–58% with ICU admission [5-6]
• Spontaneous pneumothorax in an HIV-positive patient should raise immediate suspicion for PCP [1]
• Rapid desaturation with minimal exertion
• Tachypnea >30, accessory muscle use, inability to speak in full sentences
• Acute worsening after initiation of ART (immune reconstitution inflammatory syndrome [IRIS])
• Co-infection with CMV, TB, or bacterial pathogens — consider if atypical features or poor response to therapy [1][4]

3. Medications

• Medication contributors to PCP risk:
  • Corticosteroids ≥20 mg prednisone equivalent daily for ≥4 weeks [2][7]
  • Alemtuzumab, temozolomide, purine analogs, calcineurin inhibitors, anti-TNF agents, rituximab [7-8]
  • Corticosteroids and calcineurin inhibitors may mask symptoms, delaying diagnosis [4]
• Treatment (first-line): TMP-SMX (TMP 15–20 mg/kg/day and SMX 75–100 mg/kg/day) IV divided q6–8h for 21 days; switch to PO after clinical improvement [1]
• Alternatives for TMP-SMX intolerance:
  • Primaquine 30 mg base PO daily + clindamycin (IV 600 mg q6h or 900 mg q8h, or PO 450 mg q6h) — preferred alternative by many clinicians [1]
  • IV pentamidine 4 mg/kg daily (second-line for severe disease) [1]
  • Atovaquone 750 mg PO BID (mild-to-moderate disease only) [1]
• Adjunctive corticosteroids for moderate-to-severe PCP (PaO₂ <70 or A-a gradient ≥35): Prednisone 40 mg BID days 1–5 → 40 mg daily days 6–10 → 20 mg daily days 11–21 [1]
• Contraindicated: Leucovorin during acute PCP treatment (associated with higher failure rates) [1]
• Caution: Check G6PD before dapsone or primaquine. Dose-adjust TMP-SMX for renal impairment. [1]

4. Diet

• No specific dietary triggers or restrictions
• Ensure adequate hydration, particularly with IV TMP-SMX (risk of crystalluria) and pentamidine
• Maintain adequate caloric intake — patients are often cachectic with advanced immunosuppression
• Atovaquone must be taken with food (fatty meal) to ensure adequate absorption [9]

5. Review of Systems

• Pulmonary: dyspnea (exertional → rest), cough (dry), chest tightness, pleuritic pain
• Constitutional: fever, night sweats, weight loss, fatigue, anorexia
• Oropharyngeal: oral thrush (suggests CD4 <200)
• GI: diarrhea, nausea (may indicate extrapulmonary Pneumocystis or co-infections)
• Neurologic: headache, focal deficits (consider CNS toxoplasmosis, cryptococcal meningitis as concurrent OIs)
• Dermatologic: rash, Kaposi sarcoma lesions
• Extrapulmonary Pneumocystis is rare (<2.5%) but can involve spleen, liver, eye, bone marrow, lymph nodes [10]

6. Collateral History and Family History

• Collateral: Confirm medication adherence (ART, prophylaxis), recent changes in immunosuppression, prior OI history, recent hospitalizations or exposures to immunocompromised patients (nosocomial clusters described) [1]
• Determine if patient is aware of HIV status — most PCP now occurs in patients unaware of their HIV infection or not in care [1]
• Social context: housing instability, substance use, barriers to medication access
• Family history is generally not contributory unless evaluating for primary immunodeficiency in younger patients

7. Risk Factors

• HIV/AIDS with CD4 <200 cells/mm³ — ~90% of HIV-associated PCP occurs at this threshold [1]
• Solid organ transplant — highest risk within first 6 months post-transplant [7-8]
• Hematologic malignancy (especially ALL, non-Hodgkin lymphoma) [7][11]
• Prolonged corticosteroid use (≥20 mg prednisone equivalent daily for ≥4 weeks) [2][7]
• Allogeneic HCT, CAR T-cell therapy [7]
• Autoimmune/inflammatory diseases on immunosuppressive therapy (vasculitis, SLE, inflammatory myopathies) [11-12]
• Alemtuzumab, temozolomide, purine analogs, rituximab, anti-TNF agents [7]
• Absence of PCP prophylaxis — the single most important modifiable risk factor [5]
• CMV co-infection, hypogammaglobulinemia, lymphopenia [8]

8. Differential Diagnosis

• Bacterial pneumonia (community-acquired or healthcare-associated) — more acute onset, productive cough, lobar consolidation, leukocytosis
• Tuberculosis — subacute course, upper lobe cavitation, lymphadenopathy; can co-exist with PCP [1]
• CMV pneumonitis — especially in transplant recipients; often co-occurs with PCP
• Pulmonary Kaposi sarcoma — nodular infiltrates, pleural effusions, skin/mucosal lesions
• Invasive pulmonary aspergillosis — nodular/cavitary lesions, halo sign on CT; neutropenic patients
• Cryptococcal pneumonia — often with concurrent meningitis
• Histoplasmosis/coccidioidomycosis — endemic areas, diffuse infiltrates
• Drug-induced pneumonitis (methotrexate, bleomycin) — temporal relationship with drug exposure
• Pulmonary edema — bilateral ground-glass but with cardiomegaly, effusions, B-lines on POCUS
• Distinguishing features of PCP: bilateral perihilar ground-glass opacities, absence of pleural effusion, elevated β-D-glucan and LDH, subacute course in HIV [1-2]

9. Past Medical History

• Prior PCP episode — high risk of recurrence without secondary prophylaxis
• HIV/AIDS: CD4 nadir, viral load, ART history, prior OIs
• Transplant: type, time since transplant, current immunosuppression regimen, CMV status
• Malignancy: type, chemotherapy regimen, recent intensification
• Autoimmune disease: current immunosuppressive agents, recent steroid taper
• Prior sulfa allergy (impacts treatment and prophylaxis options)
• G6PD deficiency status (relevant for dapsone/primaquine use)

10. Physical Exam

• Vital signs: Tachypnea, tachycardia, fever (present in ~80–87% of cases), hypoxemia (most characteristic finding) [1][4]
• Lung exam: Often normal at rest in mild disease — this is a classic pearl. With exertion, diffuse dry "cellophane" rales may be heard [1-2]
• Oral exam: Thrush (oropharyngeal candidiasis suggests CD4 <200)
• Skin: Kaposi sarcoma lesions, wasting, dermatologic signs of immunosuppression
• Lymphadenopathy: Generalized LAD may suggest HIV or lymphoma
• Ambulatory desaturation test: Walk the patient — desaturation with exertion is a sensitive (though nonspecific) finding [1]
• Signs of respiratory failure: Accessory muscle use, nasal flaring, cyanosis, inability to speak in full sentences

11. Lab Studies

• ABG/VBG: Assess PaO₂ and calculate A-a gradient — critical for severity classification and steroid decision [1]
  • Mild: PaO₂ ≥70 mmHg or A-a gradient <35
  • Moderate: A-a gradient 35–45
  • Severe: A-a gradient ≥45
• Serum (1,3)-β-D-glucan: High sensitivity (~90%); levels >80–100 pg/mL support diagnosis. Low levels (<80 pg/mL) have high negative predictive value [1][13-15]
• LDH: Elevated (often >500 U/L) — sensitive but nonspecific; correlates with disease severity and predicts mortality (cutoff ~495 U/L) [1][5]
• CBC with differential: Lymphopenia common; check absolute lymphocyte count
• CD4 count and HIV viral load (if HIV status unknown or not recently checked)
• CMP: Renal function (for TMP-SMX dosing), hepatic function, potassium (TMP-SMX causes hyperkalemia)
• Serum albumin: Often depressed [10]
• Blood cultures: Rule out concurrent bacteremia
• CMV PCR: If transplant recipient or concern for co-infection

12. Imaging

• Chest X-ray (first-line): Classic finding is bilateral, diffuse, symmetrical ground-glass interstitial infiltrates in a perihilar "butterfly" pattern. However, CXR can be normal in early/mild disease. [1-2]
• CT chest (thin-section, non-contrast) — gold standard imaging:
  • Ground-glass opacities (patchy or diffuse) — most characteristic finding [1][13]
  • Cystic lesions/pneumatoceles (associated with HIV/AIDS)
  • Normal CT has high negative predictive value — effectively rules out PCP [1]
• Atypical presentations: Nodules, upper-lobe predominance (associated with aerosolized pentamidine prophylaxis), pneumothorax, pneumomediastinum [1]
• Findings suggesting alternative diagnosis: Cavitation, pleural effusion, lobar consolidation — uncommon in PCP and should prompt evaluation for co-infection or alternative pathology [1]
• Imaging is unnecessary if CT is normal and clinical suspicion is low

13. Special Tests

• Induced sputum with hypertonic saline: Sensitivity 50–90% (higher in HIV due to greater organism burden); first-line non-invasive diagnostic step [1]
• Bronchoalveolar lavage (BAL): Diagnostic procedure of choice — sensitivity 90–99% with appropriate staining [1]
  • Staining: Direct immunofluorescence (DFA) preferred (highest sensitivity ~95%) [1][13]
  • Methenamine silver, toluidine blue (stain cyst wall); Giemsa/Wright (stain trophic forms) [1]
• PCR on respiratory specimens: Highly sensitive; quantitative PCR (qPCR) preferred to help distinguish colonization from disease [1][16]
• Combined testing (respiratory PCR + serum β-D-glucan) improves diagnostic certainty — PPV 72% when both positive vs. 63% for PCR alone [11]
• Key pearl: Treatment should not be delayed pending diagnostic confirmation — P. jirovecii persists in specimens for days to weeks after therapy initiation [1]

14. ECG

• ECG is not a primary diagnostic tool for PCP
• Obtain ECG if:
  • Tachycardia or arrhythmia on exam
  • Planning IV pentamidine (risk of QT prolongation, torsades de pointes)
  • Concern for myocarditis or pericarditis (rare extrapulmonary involvement)
• Monitor for hyperkalemia-related ECG changes during TMP-SMX therapy (peaked T waves, widened QRS)

15. Assessment

Severity stratification (per NIH/IDSA OI Guidelines): [1]

• Mild: PaO₂ ≥70 mmHg, A-a gradient <35 — can be treated outpatient with oral therapy
• Moderate: A-a gradient 35–45 — requires hospitalization, adjunctive steroids
• Severe: A-a gradient ≥45 — high risk of respiratory failure, ICU consideration

Typical presentation: Subacute progressive dyspnea + dry cough + fever in an immunocompromised patient with bilateral ground-glass opacities and hypoxemia out of proportion to exam findings.

Atypical presentations to recognize: Normal CXR (get CT), upper-lobe disease (pentamidine prophylaxis), spontaneous pneumothorax, extrapulmonary disease. [1]

Complications: ARDS, pneumothorax, respiratory failure requiring mechanical ventilation, IRIS after ART initiation, treatment-related toxicity (TMP-SMX: rash, cytopenias, hyperkalemia, hepatitis, Stevens-Johnson syndrome). [1-2]

Prognosis: LDH at presentation is an independent predictor of mortality — LDH >495 U/L predicted death with 70% sensitivity and specificity. [5] Overall in-hospital mortality 25%; rises to 58% with ICU admission. [5]

16. Treatment Plan

Initial stabilization

• Supplemental O₂ to maintain SpO₂ >90%; escalate to HFNC, NIV, or intubation as needed
• Obtain ABG for severity classification before initiating therapy

Preferred therapy (all severity levels): [1]

• TMP-SMX (TMP 15–20 mg/kg/day + SMX 75–100 mg/kg/day) IV divided q6–8h
• Switch to PO after clinical improvement
• Total duration: 21 days

Adjunctive corticosteroids (moderate-to-severe: PaO₂ <70 or A-a gradient ≥35): [1]

• Prednisone 40 mg PO BID × days 1–5
• Prednisone 40 mg PO daily × days 6–10
• Prednisone 20 mg PO daily × days 11–21
• Start within 72 hours of anti-PCP therapy (ideally concurrently)
• IV methylprednisolone at 80% of prednisone dose if unable to take PO

For non-HIV patients: Adjunctive steroids are more controversial. A 2025 RCT (PIC trial) and prior meta-analyses suggest potential benefit only in those with severe hypoxemic respiratory failure (PaO₂ <60 mmHg). [3][17]

Alternatives for TMP-SMX intolerance: [1]

• Primaquine + clindamycin (preferred alternative — more effective and less toxic than pentamidine)
• IV pentamidine 4 mg/kg daily (severe disease)
• Atovaquone 750 mg PO BID with food (mild-to-moderate only)

Additional considerations

• Monitor potassium, renal function, CBC during TMP-SMX therapy
• In HIV patients: initiate ART as soon as feasible (monitor for IRIS)
• In transplant/immunosuppressed patients: discuss reduction of immunosuppression with transplant/oncology team [4]
• Clinical improvement may take up to 1 week — do not consider treatment failure before 5–7 days [13]

17. Disposition

• Admit if:
  • PaO₂ <70 mmHg or A-a gradient ≥35 (moderate-to-severe disease)
  • Requiring supplemental oxygen
  • Unable to tolerate oral medications
  • Significant comorbidities, hemodynamic instability
  • New HIV diagnosis requiring workup
• ICU admission if: respiratory failure, need for HFNC/NIV/intubation, hemodynamic instability, ARDS
• Outpatient treatment is appropriate for mild PCP (PaO₂ ≥70, A-a gradient <35) in reliable patients who can take oral medications and follow up closely [1-2]
• Observation may be appropriate for borderline cases with close monitoring of oxygenation
• Specialist consultation triggers:
  • Infectious disease: all cases (especially for diagnostic confirmation and treatment guidance)
  • Pulmonology: for bronchoscopy/BAL if needed
  • HIV specialist: new diagnosis or treatment-experienced patients with virologic failure
  • Critical care: respiratory failure or hemodynamic instability

18. Follow Up / Return Precautions

• Follow-up timing:
  • Outpatient: within 3–5 days of discharge or treatment initiation to reassess oxygenation and tolerance
  • Repeat ABG or pulse oximetry at follow-up
  • Complete 21-day treatment course
• Secondary prophylaxis: After completing treatment, continue PCP prophylaxis (TMP-SMX 1 DS tablet daily or 3×/week) until CD4 >200 cells/mm³ for ≥3 months on ART [1][13]
• Return precautions — instruct patients to return immediately for:
  • Worsening shortness of breath or new chest pain
  • Fever not improving after 5–7 days of treatment
  • Rash (especially widespread or involving mucous membranes — concern for SJS/TEN)
  • Inability to take medications
  • Syncope or near-syncope
• Expected recovery: Clinical improvement typically begins within 4–8 days; radiographic improvement lags behind clinical improvement. Full recovery may take weeks. [13]
• Patient counseling: Emphasize importance of completing full 21-day course, adherence to prophylaxis after treatment, and engagement with HIV or immunosuppression management

References

1. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. — Constance Benson, John Brooks, Shireesha Dhanireddy, et al Infectious Diseases Society of America; Office of AIDS Research Advisory Council (2025). 2025.

2. Pneumocystis Pneumonia. — Thomas CF, Limper AH. The New England Journal of Medicine. 2004.

3. Adjunctive Corticosteroids in Non-Aids Patients With Severe Pneumocystis Jirovecii Pneumonia (PIC): A Multicentre, Double-Blind, Randomised Controlled Trial. — Lemiale V, Resche-Rigon M, Zerbib Y, et al. The Lancet. Respiratory Medicine. 2025.

4. Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. — Fishman JA, Gans H, AST Infectious Diseases Community of Practice. Clinical Transplantation. 2019.

5. Clinical Course, Treatment and Outcome of Pneumocystis Pneumonia in Immunocompromised Adults: A Retrospective Analysis Over 17 years. — Schmidt JJ, Lueck C, Ziesing S, et al. Critical Care. 2018.

6. Outcome and Prognostic Factors of Pneumocystis Jirovecii Pneumonia in Immunocompromised Adults: A Prospective Observational Study. — Gaborit BJ, Tessoulin B, Lavergne RA, et al. Annals of Intensive Care. 2019.

7. Prevention and Treatment of Cancer-Related Infections. — Updated 2026-03-11. National Comprehensive Cancer Network.

8. Pneumocystis Jiroveci. — Fishman JA. Seminars in Respiratory and Critical Care Medicine. 2020.

9. HIV Infection — Screening, Diagnosis, and Treatment. — Saag MS. The New England Journal of Medicine. 2021.

10. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV. — Bill G. Kapogiannis, Franklin Yates, Wei Li, et al Office of AIDS Research Advisory Council (2025). 2025.

11. Pneumocystis Jirovecii Pneumonia in Intensive Care Units: A Multicenter Study by ESGCIP and EFISG. — Giacobbe DR, Dettori S, Di Pilato V, et al. Critical Care. 2023.

12. How to Diagnose and Treat a Patient Without Human Immunodeficiency Virus Infection Having Pneumocystis Jirovecii Pneumonia?. — Hänsel L, Schumacher J, Denis B, et al. Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2023.

13. Fungal Infections in HIV/­AIDS. — Limper AH, Adenis A, Le T, Harrison TS. The Lancet. Infectious Diseases. 2017.

14. Diagnostic Accuracy of the 1,3-Beta-D-Glucan Test and Lactate Dehydrogenase for Pneumocystis Pneumonia in Non-Hiv Patients. — Sun R, Lv D, Xiao M, et al. Scientific Reports. 2021.

15. Serum Indicators for the Diagnosis of Pneumocystis Pneumonia. — Tasaka S, Hasegawa N, Kobayashi S, et al. Chest. 2007.

16. An Overview of the Laboratory Diagnosis of Pneumocystis Jirovecii Pneumonia. — Jaramillo Cartagena A, Asowata OE, Ng D, Babady NE. Journal of Clinical Microbiology. 2025.

17. Low-Dose Corticosteroids for Critically Ill Adults With Severe Pulmonary Infections: A Review. — Pirracchio R, Venkatesh B, Legrand M. The Journal of the American Medical Association. 2024.